NEW YORK (
CHANGE IN RATINGS
(HHS) was upgraded to buy at TheStreet Ratings.
(MSFT - Get Report) was upgraded at Nomura to buy. $38 price target. Shareholder activism could help unlock value, Nomura said.
(PCP - Get Report) was upgraded at Wells Fargo to outperform from market perform. Company can deliver 15% annual earnings growth over the next several years, Wells Fargo said.
was initiated with an outperform rating at Oppenheimer. $300 price target. Eylea should continue to grow and the company is expanding into DME, Oppenheimer said.
was downgraded at Leerink Swann to market perform from outperform. $26 price target. Valuation call, as the company trades at a sizable premium to its peers, Leerink Swann said.
was initiated with a buy rating at Keybanc. $100 price target. Company has a strong growth profile, including exposure to Latin America, Keybanc said.
was downgraded to hold at TheStreet Ratings.
(TSLA - Get Report)
was initiated with a hold rating at Stifel Nicolaus. Valuation call, as the company still has little evidence of customer retention or success at lower price points, Stifel Nicolaus said.
(VRTX - Get Report)
was initiated with an outperform rating at Oppenheimer. $105 price target. Cystic Fibrosis treatments can continue to drive growth, Oppenheimer said.
(ZNGA - Get Report)
was initiated with a hold rating at Benchmark. $2.98 price target. New management needs to show stabilized Web trends and material mobile acceleration, Benchmark said.
Stock Comments / EPS Changes
numbers were cut at BMO Capital. Estimates were reduced through 2014. Management cut guidance, BMO Capital said. Market Perform rating and new $15 price target.
numbers were increased at UBS. Estimates were boosted through 2015. Domestic business is positioned well, ahead of the holidays, UBS said. Neutral rating and new $35 price target.
numbers were reduced at BMO Capital. Shares are now seen reaching $27. Estimates were also cut, given lower operating growth, especially in the enterprise segment, BMO Capital said. Market Perform rating.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts